

1st Half of Fiscal Year ending March 2026 Consolidated Financial Results

November 6, 2025

DAICEL CORPORATION

1. Summary

- (1) Summary

2. Financial Results - 1st Half

- (1) Financial Results and Overview
- (2) Net Sales and Operating Income by Segment
- (3) Segment Information
- (4) Balance Sheet
- (5) Cash Flow Statement
- (6) Response of Top Priority Issues

3. Forecasts - Full-Year

- (1) Forecasts / Analysis of EBITDA
- (2) Net Sales and Operating Income by Segment
- (3) Segment Information - Forecasts

4. Shareholders Return

- (1) Shareholders Return

5. Appendix

- (1) Appendix

Summary

Results of FY2026/3 1H Financial Results (vs previous year)

Net Sales 277.1 bn yen (-4.3%)

Operating Income 20.1 bn yen (-36.3%)

EBITDA 40.5 bn yen (-21.2%)

Profit attributable to owners of parent 18.8 bn yen (-41.3%)

ROIC 4.9% (-1.8pp)

Exchange Rate USD/JPY : 146 yen (FY2025/3 2Q USD/JPY : 153 yen)

Both net sales and operating income were significantly affected by foreign exchange fluctuations, resulting in a decrease in both.

- Net sales decreased. Sales of acetate tow in the Materials business decreased due to customer inventory adjustments, and resin compound business in the Engineering Plastics business transferred to an equity-method affiliate in July 2024.
- Operating income decreased due to the impact of a decrease in net sales, and an impact on carryover stock and an increase in expenses of shut-down maintenance.

Revised Forecasts of FY2026/3(vs Previous Forecasts)

Net Sales 583.0 bn yen (-2.8%)

Operating Income 46.5 bn yen (-13.9%)

EBITDA 89.5 bn yen (-7.7%)

Profit attributable to owners of parent 50.0 bn yen (-7.4%)

ROIC 4.7% (-0.7pp)

Exchange Rate (Forecast) USD/JPY : 146 yen (Previous Forecast USD/JPY : 140 yen)

Both net sales and operating income are expected to.

- Net sales is expected to decrease due to a decrease in sales volume of acetate tow attributed to customers' inventory adjustments, and a decrease in sales volume of POM in Engineering Plastics business in China.
- Operating income is expected to decrease due to the impact of temporary carbon monoxide (CO) plant troubles in Materials business as well as a decrease in net sales.

Shareholders Return

Annual dividends forecasts :

60 yen per share(Unchanged from the previous forecast)

Decided to purchase treasury stock of 15 billion yen for 11 million shares (maximum)

- Maintain stable and continuous shareholders return in accordance with the following policies; "total return ratio of 40% or more" and "dividend on equity (DOE) ratio of 4% or more" .

Y on Y:

- Both sales and operating income were significantly impacted by exchange rate fluctuation. Although sales of inflators for airbag increased mainly in China, net sales decreased due to a decline in sales of acetate tow in the Materials Business which was impacted by customer inventory adjustments, and transfer of the resin compound business to an equity-method affiliate in the Engineering Plastics Business in July 2024. Operating income decreased due to a decrease in sales volume of acetate tow in the Materials business, the impact of carryover inventory and increased costs of shut-down maintenance.
- Profit attributable to owners of parent decreased due to a gain on the sale of affiliated company shares following the transfer of Daicel Miraizu resin compound business in the second quarter of FY2025/3.

VS Forecast:

- Sales of acetate tow in the Materials business fell short of plan, due mainly to inventory adjustments by local tobacco manufacturers, although sales to major tobacco manufacturers were as planed. Regarding Engineering Plastics Business, sales volume of POM fell short of the plan due to changes in the market environment in China (supply-demand balance and market prices), despite a robust trend in LCP sales.

	25/3 1H Results	26/3 1H Forecasts*	26/3 1H Results	Y on Y		vs Forecasts	
				Change	%	Change	%
Unit: Billion Yen							
Net Sales	289.7	290.0	277.1	-12.6	-4.3%	-12.9	-4.4%
Operating Income	31.6	22.5	20.1	-11.5	-36.3%	-2.4	-10.6%
Ordinary Income	30.7	23.5	20.4	-10.4	-33.7%	-3.1	-13.3%
Profit Attributable to Owners of Parent	32.1	25.0	18.8	-13.3	-41.3%	-6.2	-24.8%
Exchange Rate USD/JPY	153	140	146				
EBITDA	51.3	43.0	40.5				

*These forecasts were announced on May 13, 2025.

Net Sales and Operating Income by Segment (Y on Y Analysis)

Unit : Billion Yen	Net Sales						
	25/3 1H Results	26/3 1H Forecasts*	26/3 1H Results	Y on Y		vs Forecasts	
				Change	%	Change	%
Medical / Healthcare	7.2	7.5	7.6	+0.4	+6.2%	+0.1	+1.8%
Smart	19.6	20.0	18.2	-1.4	-7.3%	-1.8	-9.1%
Safety	47.1	50.0	49.7	+2.7	+5.6%	-0.3	-0.6%
Materials	88.5	83.0	77.2	-11.3	-12.8%	-5.8	-7.0%
Engineering Plastics	124.5	127.0	121.9	-2.6	-2.1%	-5.1	-4.0%
Others	2.8	2.5	2.5	-0.3	-11.3%	+0.0	+0.3%
Total	289.7	290.0	277.1	-12.6	-4.3%	-12.9	-4.4%

Unit : Billion Yen	Operating Income						
	25/3 1H Results	26/3 1H Forecasts*	26/3 1H Results	Y on Y		vs Forecasts	
				Change	%	Change	%
Medical / Healthcare	0.2	-0.2	0.2	+0.0	+10.1%	+0.4	-
Smart	0.2	0.7	0.4	+0.2	+87.9%	-0.3	-42.3%
Safety	1.3	2.9	2.7	+1.4	+102.8%	-0.2	-8.2%
Materials	14.3	7.8	5.0	-9.4	-65.3%	-2.8	-36.2%
Engineering Plastics	15.2	11.0	11.5	-3.7	-24.5%	+0.5	+4.3%
Others	0.3	0.3	0.4	+0.1	+16.3%	+0.1	+33.3%
Total	31.6	22.5	20.1	-11.5	+36.3%	-2.4	-10.6%

*These forecasts were announced on May 13, 2025.

Net Sales and Operating Income by Segment (Y on Y Analysis)

	Net Sales						
	25/3 1H Results	26/3 1H Results	Change	%	Analysis		
					Quantity	Prices	Exchange Rate Impact*
Unit : Billion Yen							
Medical / Healthcare	7.2	7.6	+0.4	+6.2%	+0.5	-0.0	-0.3
Smart	19.6	18.2	-1.4	-7.3%	-1.0	-0.4	-0.4
Safety	47.1	49.7	+2.7	+5.6%	+4.6	-2.0	-1.7
Materials	88.5	77.2	-11.3	-12.8%	-5.7	-5.6	-2.7
Engineering Plastics	124.5	121.9	-2.6	-2.1%	-3.3	+0.7	-3.5
Others	2.8	2.5	-0.3	-11.3%	-0.3	-	-
Total	289.7	277.1	-12.6	-4.3%	-5.3	-7.2	-8.5

	Operating Income							
	25/3 1H Results	26/3 1H Results	Change	%	Analysis			
					Quantity	Prices	Others	Exchange Rate Impact
Unit : Billion Yen								
Medical / Healthcare	0.2	0.2	+0.0	+10.1%	+0.5	-0.0	-0.4	-0.1
Smart	0.2	0.4	+0.2	+87.9%	+0.0	+0.5	-0.4	-0.3
Safety	1.3	2.7	+1.4	+102.8%	+1.8	-1.5	+1.0	-0.2
Materials	14.3	5.0	-9.4	-65.3%	+2.2	-4.3	-7.3	-1.9
Engineering Plastics	15.2	11.5	-3.7	-24.5%	-1.5	+2.6	-4.9	-0.6
Others	0.3	0.4	+0.1	+16.3%	+0.1	-	-	-
Total	31.6	20.1	-11.5	-36.3%	+3.1	-2.6	-12.0	-3.1

Segment Information – 1st Half Result (Y on Y)

■ Medical / Healthcare

Unit : Billion Yen	25/3 2Q Result	26/3 2Q Result	Y on Y	
			Change	%
Net Sales	7.2	7.6	+0.4	+6.2%
Operating Income	0.2	0.2	+0.0	+10.1%

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+0.5	Sales volume increased in both Life Sciences and Healthcare
Prices	-0.0	Impact on exchange rate fluctuations
Others	-0.4	Increased expenses due to higher research and increased sales volume

【YoY】 Net Sales & OP UP

Life Sciences: Net Sales Slightly Down (-0.1%)

- Sales volume of chiral column and related products slightly increased due to sales of stationary phases for pharmaceutical manufacturing in Europe. Sales of analytical and synthesis services slightly decreased due to foreign exchange fluctuation, even though the sales of laboratory in China launched last year increased.

Healthcare: Net Sales Up (+23.6%)

- The cosmetics and health food markets in Japan and overseas remained strong. Sales of applications for supplements were particularly strong, with significant growth in equol, leading to increased revenue.

Segment Information – 1st Half Result (Y on Y)

■ Smart

Unit : Billion Yen	25/3 2Q Result	26/3 2Q Result	Y on Y	
			Change	%
Net Sales	19.6	18.2	-1.4	-7.3%
Operating Income	0.2	0.4	+0.2	+87.9%

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+0.0	
Prices	+0.5	Decrease in raw material price
Others	-0.4	Increase in allocation of corporate expenses etc.

【YoY】 Net Sales Down / OP Up

Functional Products: Net Sales Down (-6.4%)

- Net sales of caprolactone derivatives decreased due to price competition in China and foreign exchange fluctuation.
- Net sales of cycloaliphatic epoxies decreased due to foreign exchange fluctuation, despite an expansion in market share, mainly in Europe and the US, and a recovery in demand for electronic materials market particularly for electronic substrates.

Advanced Technology: Net Sales Down (-8.4%)

- Net sales of solvents for electronic materials increased due to steady semiconductor market trend. Net sales of polymers for photoresists decreased due to timing differences in customer production, despite the positive impact of sales expansion. Net sales of high performance films decreased due to a decrease in sales volume of display film for in-vehicle application, despite a recovery trend in demand for release films for battery applications.

Segment Information – 1st Half Result (Y on Y)

■ Safety

Unit : Billion Yen	25/3 2Q Result	26/3 2Q Result	Y on Y	
			Change	%
Net Sales	47.1	49.7	+2.7	+5.6%
Operating Income	1.3	2.7	+1.4	+102.8%

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+1.8	Increase in sales volume of inflators, improved productivity at a production site in North America
Prices	-1.5	Tariff impact, exchange rate impact
Others	+1.0	Productivity improvement at North American production sites and cost reduction

【YoY】 Net Sales & OP Up

Mobility: Net Sales Up (+7.2%)

- Although the same period of the previous fiscal year was affected by issues such as the Japanese automobile certification misconduct issue, in the second quarter of the current fiscal year, sales of inflators increased due to factors such as the recovery of production by Chinese automobile manufacturers as a result of government stimulus measures in the Chinese market and the expansion of sales through the addition of new production lines in India.

Industry: Net Sales Down (-11.0%)

- From the second half of the fiscal year ended March 2025, we received orders for new businesses targeting China and expanded sales, but net sales decreased due to a decline in sales of external sales initiators.

Segment Information – 1st Half Result (Y on Y)

■ Materials

Unit : Billion Yen	25/3 2Q Result	26/3 2Q Result	Y on Y	
			Change	%
Net Sales	88.5	77.2	-11.3	-12.8%
Operating Income	14.3	5.0	-9.4	-65.3%

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+2.2	(+) Recovery from the operational issues at the carbon monoxide plant (-) Decrease in sales volume of acetate tow
Prices	-4.3	Decline in acetate acid market condition, foreign exchange fluctuation
Others	-7.3	Impact of moving average and increase in expenses of the full acquisition of Toyama Filter Tow, etc.

【YoY】 Net Sales & OP Down

Acetyl: Net Sales Down (-14.9%)

- Net sales decreased due to a decrease in sales volume of acetate tow resulting from inventory adjustments mainly in local manufacturers, and the impact of foreign exchange rates.

Chemical: Net Sales Up (-7.1%)

- Sales of cellulose acetate decreased due to a decline in demand for textile applications in the Chinese market, although the sales volume for LCD applications remained at the same level as the previous fiscal year due to rush demand of LCD panel market caused by subsidy programs by Chinese government and pre-implementation of additional U.S. tariffs.
- Sales of 1,3-BG increased due to an increase in sales volume on the background of steady trend in domestic and overseas cosmetic markets, sales expansion to overseas market, and increased adoption of our products under U.S.-China trade friction, leading to higher sales volume.

Segment Information – 1st Half Result (Y on Y)

■ Engineering Plastics

Unit : Billion Yen	25/3 2Q Result	26/3 2Q Result	Y on Y	
			Change	%
Net Sales	124.5	121.9	-2.6	-2.1%
Operating Income	15.2	11.5	-3.7	-24.5%

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	-1.5	(-)Impact from the transference the resin compound business, decrease in sales volume of POM (+)Increased sales volume of LCP etc.
Prices	+2.6	Decrease in raw material price, foreign exchange fluctuation
Others	-4.9	Increase in depreciation, impact from shut-down maintenance, increase in personnel expenses and information and communication technology (ICT) related expenses

【YoY】 Net Sales & OP Down

Polyplastics Co., Ltd.: Net Sales Slightly Up 0(+0.5%)

Chinese automotive manufacturers are performing well in China, while Japanese manufacturers are struggling. Net sales remained a slightly increase due to foreign exchange fluctuation and a decrease in sales volume of POM, despite a strong sales of LCP.

- Sales volume of POM decreased due to sluggish sales for various industrial sectors resulting from price competition.
- Sales volume of PBT increased due to steady demand for automotive application.
- Sales volume of PPS increased due to strong demand in server application, as well as in automotive application.
- Sales volume of LCP increased due to strong demand in server application and sharp rise in application for electronic devices such as smartphone and personal computers driven by China's consumer goods trade-in program. The plant in Taiwan, established to expand production capacity started operation in February 2025, reached full-scale operation in May 2025.

Daicel Miraizu Ltd.: Net Sales Down (-18.8%)

Net sales of Daicel Miraizu decreased due to the transference the resin compound business to Novacel Co., Ltd. (equity-method affiliate) in July 2024.

Segment Information (VS 1st Half Forecast)

Unit : Billion Yen

		FY2026/3 1H Forecast*	FY2026/3 1H Result	VS 1st Half Forecast*	VS 1st Half Forecast
Medical / Healthcare	Net Sales	7.5	7.6	+0.1	Net sales exceeded the forecast / Operating income exceeded the forecast - Regarding Life Sciences business, sales exceeded the plan due to sales of stationary phases for pharmaceutical manufacturing in Europe. - Regarding Healthcare business, sales exceeded the plan due to a robust sales of equol, functional food material.
	Operating Income	-0.2	0.2	+0.4	
Smart	Net Sales	20.0	18.2	-1.8	Net sales fell short of the forecast / Operating income fell short of the forecast - The sales of cycloaliphatic epoxies exceeded the plan due to sales expansion for high value applications. However, the sales of caprolactone derivatives fell short of the plan. - Regarding solvents for electronic materials, the domestic semiconductor market is steady, but sales for LCD panels fell short of plans due to lower-than-expected demand, and sales for automotive paints in Europe also fell short of plans. Regarding high-performance films, the demand for electronic vehicle in China did not meet expectation, therefore the sales fell short of the plan due to a delay on the product launch.
	Operating Income	0.7	0.4	-0.3	
Safety	Net Sales	50.0	49.7	-0.3	Net sales fell short of the forecast / Operating income fell short of the forecast Net sales of inflator fell short of the plan due to sluggish sales by some Japanese automakers in the Japanese market, lower-than-expected growth in automobile sales in the Chinese market, and the partial impact of additional tariffs imposed by the US.
	Operating Income	2.9	2.7	-0.2	

*These forecasts were announced on May 13, 2025.

Segment Information (VS 1st Half Forecast)

Unit : Billion Yen

		FY2026/3 1H Forecast*	FY2026/3 1H Result	VS 1st Half Forecast*	VS 1st Half Forecast
Materials	Net Sales	83.0	77.2	-5.8	Net sales fell short of the forecast / Operating income fell short of the forecast - Net sales fell short of the plan due to a sluggish sales of acetate tow to local tobacco manufactures, even though sales to major tobacco manufactures proceeded as planned. - Operating income also fell short of the plan due to carbon monoxide plant troubles as well as a decrease in sales of acetate tow.
	Operating Income	7.8	5.0	-2.8	
Engineering Plastics	Net Sales	127.0	121.9	-5.1	Net sales fell short of the forecast / Operating income exceeded the forecast Sales of POM decreased in Chinese market mainly resulting from a drop in export from China to the US. Sales volume of COC fell short of the plan due to a decrease in sales caused by sluggish demand recovery for eco-friendly packaging materials. On the other hand, operating income exceeded the plan due to foreign exchange fluctuation.
	Operating Income	11.0	11.5	+0.5	

*These forecasts were announced on May 13, 2025.

Balance Sheet

Unit : Billion Yen		Mar. 31, 2025	Sep. 30, 2025	Change
Total Current Assets		395.6	390.7	-4.9
	Cash and Deposits	65.1	64.7	-0.5
	Notes and Accounts Receivable-trade	113.9	102.8	-11.1
	Inventories	177.9	186.0	+8.1
	Other	38.7	37.2	-1.4
Total Non-Current Assets		418.2	458.2	+40.0
	Property, Plant and Equipment	319.4	348.9	+29.5
	Intangible Fixed Assets	10.6	10.9	+0.2
	Investments and Other Assets	88.1	98.4	+10.3
Total Assets		813.8	848.9	+35.1
Liabilities		438.8	454.7	+15.9
	Interest-bearing Liabilities	286.1	295.8	+9.7
	Other	152.7	158.9	+6.2
Total Net Assets		375.0	394.2	+19.2
Total Liabilities and Net Assets		813.8	848.9	+35.1

- Of the total asset increase, the foreign exchange impact was an increase of 12.7 billion yen.
- The reason of a rise in inventories is an increase in stock of acetate tow and POM of Polyplastics due to timing differences in sales and stockpiling inventories for shut-down maintenance. We will review production plans in the 2nd half of the fiscal year to promote inventory reduction and reduce year-end inventories to below the previous year's turnover days.
- Property, plant and equipment increased due mainly to an investment for increase in production capacity of POM, LCP and COC in Polyplastics.
- Investments and other assets increased mainly due to the rise in market value of investment securities.
- The increase in interest-bearing debt is primarily due to the rise in long-term borrowings related to Polyplastics' production expansion investments in Germany and China.

Cash Flow Statement

Unit : Billion Yen		2025/3 1H	2026/3 1H
	Cash Flows from Operating Activities	50.7	32.8
	Cash Flows from Investing Activities	-29.4	-26.5
Free Cash Flows		21.4	6.2
Cash Flows from Financing Activities		-24.0	-7.8
Other		-1.3	1.3
Net Increase (Decrease) in Cash and Cash Equivalents		-4.0	-0.3
Cash and Cash Equivalents at End of Period		64.4	64.4

- Operating cash flow was decreased to 32.8 billion yen, due to factors including a decrease in sales volume. Furthermore, investment cash flow remained at a high level of -26.5 billion yen, primarily due to investments in Polyplastics' increased production plant.
- As a result, free cash flow was decreased to 6.2 billion yen.
- Cash flows from financing activities were -7.8 billion yen, due mainly to an increase in interest-bearing debt from long-term borrowings for capital investment.

【Overall Strategy】

We will rigorously manage the pricing of our mainstay product, POM, aiming to increase sales volume and maximize profits. Furthermore, for the strong-performing LCP and PPS used in servers, we will leverage Polyplastics' strengths to contribute to overall profit growth.

1)POM Sales Strategy in the Chinese Market

China Market Conditions:

- By aggressive Chinese government economic stimulus measures, China **achieved a real GDP growth rate of 5.3% year-on-year** in the first half of 2025. Domestic consumption in China increased due to home appliance replacement policies, leading to an expansion of domestic demand. While exports to U.S. had been decreasing due to U.S. tariffs, the export condition improved in May 2025 due to U.S. tariffs reduction, and manufacturing investment remained robust. In the automotive industry, Chinese manufacturers performed well, but Japanese manufacturers saw a decline.

Issues for Polyplastics :

【Used for Industries】

- We presumed that export volumes across various industries had declined due to increased tariffs on exports from China to the United States. Furthermore, the commencement of production by new POM suppliers has created a situation of oversupply. As a result, Chinese POM manufacturers have lowered their selling prices below cost levels, leading to difficulties for our company in sales in China.

【Used for Automotive】

- Japanese manufacturers showed weakness, with sales volume declining.

Measures:

【 Used for Industries 】

- **Responding to Price Competition:** For industrial customers, we will closely monitor market reactions, strengthen quality differentiation and manage prices for each customer, strive to secure sales volume, and enhance competitiveness against emerging suppliers.

【Used for Automotive】

- **Diversification of Customer Base:** We aim to increase our market share to Chinese customers with a high growth potential, thereby strengthening our presence in the Chinese market (the sales volume in the automotive sector in China is projected to increase by approximately 10% compared to the previous fiscal year).

Outlook :

- For the fiscal year ending March 2026, while sales to various industries declined significantly in the first half, sales volume is expected to decrease by only approximately 2% from the previous period due to the implementation of sales strategies.
- For the fiscal year ending March 2027, we plan to commence operations of the second phase 60,000-ton capacity expansion plant starting in the third quarter. This will establish a local production and consumption system, eliminating the impact of anti-dumping duties. We will **capture the 3-4% annual growth rate in domestic demand in China.**

2) LCP Sales for Growing High-Speed Communication Servers

【Server Market Overview】

- Total server production volume: 13 million units, including 2.3 million AI servers (2025 fiscal year forecast)
- Overall server market growth rate from fiscal year 2024 to fiscal year 2027: 7% (AI servers: 22% market growth rate)
- Average number of cooling fans installed per server: 13
- Amount of LCP used per server: 13 cooling fans × 20g/fan = 260g/server

【Polyplastics' LCP for Servers】

- It is projected that Polyplastics' LCP sales volume is 1,500 tons/year by fiscal 2025, maintaining a top global market share of 43%.
- The start of operations at the new plant in Taiwan strengthens the stable supply system to customers and enhances reliability.

【Polyplastics' LCP】 World's Top Market Share

- In 2Q of the FY2026/3, LCP demand for servers was strong in addition to existing PC and smartphone applications, and this trend is expected to continue throughout the full year.
- The new plant in Taiwan, which started operation since February 2025, is at full capacity. Sales volume increased by 19% (YoY) in 2Q of the FY2026/3, and full-year growth is expected to 21% (YoY).
- Looking ahead to the FY2027/3, with the market growing at an annual rate of 4%, sales volume is expected to increase by 5% (compared to the previous fiscal year), anticipating continued strength in the server market.

*In PPS as well, alongside existing automotive applications, the shift to optical communication is advancing due to increased data volumes, leading to a rise in MT ferrule applications. ⇒ Sales volume is expected to increase by 2% (YoY) for the full fiscal year.

Strengthening the Engineering Plastics Business

Strengthen the Engineering plastics business, a key growth driver, through the integration of Daicel and Polyplastics and the expansion of the product lineup.

Begin Discussions of Integration with Polyplastics for New Daicel

Effective April 1, 2026, all operations of Polyplastics Co., Ltd. (excluding its subsidiary and affiliate shareholdings and management businesses) will be integrated into Daicel, aiming to maximize corporate value.

【Purpose of Integration】

- Speed up the implementation of measures to further grow the Engineering Plastics business, a key focus area for the Daicel Group.
- Make swift decisions to fully leverage resources, including the talent held by both companies.
- Aim to streamline the Daicel Group's corporate functions into a lean, elite team.

Strengthening the Engineering Plastics Business

Effective January 1, 2026, Mitsui Chemicals, Inc. will entrust Polyplastics with the sales operations for polyamide resin (ARLEN®) and polyimide resin (AURUM®). Polyplastics will exclusively handle sales-related functions, including customer support, new business development, and technical support. Both companies will work to strengthen the Engineering plastics business and will also explore further deepening their collaboration going forward.

【 Purpose of the Partnership 】

- Mitsui Chemicals aims to achieve further business growth by leveraging Polyplastics' customer network and solution-providing capabilities to meet the expanding demand for high-performance engineering plastics in the automotive and electrical/electronics sectors.
- Polyplastics will enhance its solution-providing capabilities for a broader customer base by enriching its product portfolio through sales activities for both products.

● Productivity Improvement at U.S. Safety Business Sites and Tariff Impact

Productivity improvements at the U.S. facility are progressing smoothly. While affected by U.S. tariffs, we will strive to secure profits through price pass-through.

Productivity Improvement at a U.S. production site

FY2026 2Q	Maintained 80% operational availability rate from previous fiscal year's 4Q. Achieved surplus excluding U.S. tariff impact. - Despite reduced inflator volumes, productivity improvements and cost reduction initiatives offset the impact. - Implemented man-hour reductions through multi-skilling of direct personnel and consolidation of accounting departments.
FY2026 Full-Year Forecast	Aim to stabilize by maintaining an 80% or higher operating rate, while further improving the operating rate going forward. - U.S. auto demand: -5% vs. plan; Company's inflator sales volume: -1.2% - Plan to achieve profitability for the full year through equipment automation and outsourcing of logistics operations. The Safety Business as a whole expects an operating margin improvement of at least 2 percentage points compared to the previous fiscal year.

● Impact of U.S. Tariffs: Full-Year Forecast - Approximately ¥1.1 billion in increased costs

Breakdown	Full-year forecast: Total tariffs approximately ¥2.2 billion; of this, approximately ¥1.1 billion in price pass-through is planned to be implemented with a half-year delay.
Tariff-affected products	Raw materials (metal parts): ¥550 million impact Inflator products manufactured at overseas sites: ¥1.65 billion impact

Response of Top Priority Issues : Materials Business

Material Business

Due to factors such as reduced local sales volume of acetate tow and issues at the CO plant, earnings are expected to fall below the initial plan (approximately ¥3 billion lower than the initial plan). We will strengthen cost reductions to maintain profitability while working to reduce inventory, contributing to improved ROIC.

Acetate tow (revised forecast: below initial plan, flat compared to previous period)

Market Environment

- Demand trends for tobacco and filters remain unchanged, continuing at a slight decline of just under 1%.
- Competition in the local market intensified due to increased production and market entry by Chinese competitors.

Daicel's Situation

- **Contracts with major tobacco manufacturers are progressing as planned**, with sales prices expected to remain stable.
- Meanwhile, the **initial sales expansion strategy targeting local manufacturers** has **fallen short of initial plan** due to inventory adjustments of local manufacturers and price competition.
- Excess distribution inventory held by local manufacturers is expected to gradually resolve starting around January 2026, with sales projected to pick up from the second half of next fiscal year.
- We will shorten the CCC and improve ROIC by implementing flexible inventory management to reduce inventory in line with declining sales volumes.

CO Plant* Status

We implemented permanent countermeasures during 1Q shut-down maintenance; **temporary trouble occurred in 2Q after shut-down maintenance.**

Impact amount relative to initial forecast

(Unit : Billion Yen)	2026/3 Forecast
Impact of Troubles	-3.2
Acetic Acid Product Mix Impact**	1.2
Total	-2.0

*The CO plant produces carbon monoxide, the primary raw material for acetic acid, using coal. Previously, asphalt was used as feedstock, but with the aging plant's renewal, coal was adopted as the new feedstock, and the plant commenced operations in February 2024. While the original specifications assumed the use of Russian coal, the global situation necessitated switching to Canadian coal. During the fiscal year ending March 2025, plant malfunctions occurred due to the difference in coal types.

**Acetic acid scheduled for sale that could not be produced during the trouble period was procured externally (at a lower price than our own product).

<Revised Forecast>

- Although the yen weakened more than anticipated during the first half, we are revising our full-year forecast due to product sales trends and temporary issues at the CO plant.
- Acetate tow sales are expected to decline from the initial forecast due to reduced sales volumes resulting from customer inventory adjustments and decreased POM sales volumes at Polyplastics. Operating Income is expected to decrease from the initial forecast due to issues such as CO plant troubles, despite steady progress in productivity improvements at the Safety business's U.S. base.
- Profit attributable to owners of parent is projected to be ¥50 billion, including subsidy income related to capital investment

Unit : Billion Yen	25/3 Results	26/3 Forecasts	26/3 Revised forecasts	Y on Y		vs Forecasts			25/3 Results	26/3 Forecasts	26/3 Revised forecasts
				Change	%	Change	%				
Net Sales	586.5	600.0	583.0	-3.5	-0.6%	-17.0	-2.8%	EBITDA	102.4	97.0	89.5
Operating Income	61.0	54.0	46.5	-14.5	-23.8%	-7.5	-13.9%	ROE	13.8%	14.8%	13.8%
Ordinary Income	62.3	56.0	47.5	-14.8	-23.8%	-8.5	-15.2%	ROIC	6.1%	5.4%	4.7%
Profit attributable to owners of parent	49.5	54.0	50.0	+0.5	+1.1%	-4.0	-7.4%	ROA	6.0%	6.6%	6.2%
								EPS(Yen)	181.44	203.67	188.33
Exchange Rate USD/JPY	153	140	146								

Analysis of EBITDA


Quantity Impact

Engineering Plastics -6.8
Materials -2.4
Safety -1.2

Price Impact

Selling Price: -3.5
Material -2.3, Engineering Plastics -1.2
Purchase Price: +5.1
Material +3.8, Safety +0.9

Unit : Billion Yen



Net Sales and Operating Income by Segment (Forecasts)

Unit : Billion Yen	Net Sales						
	25/3 Results	26/3 Forecasts	26/3 Revised forecasts	Y on Y		vs Forecasts	
				Change	%	Change	%
Medical / Healthcare	14.4	15.5	16.0	+1.6	+10.8%	+0.5	+3.2%
Smart	37.3	40.5	39.0	+1.7	+4.5%	-1.5	-3.7%
Safety	97.6	101.0	103.5	+5.9	+6.0%	+2.5	+2.5%
Materials	183.4	181.5	172.0	-11.4	-6.2%	-9.5	-5.2%
Engineering Plastics	248.0	256.0	247.0	-1.0	-0.4%	-9.0	-3.5%
Others	5.8	5.5	5.5	-0.3	-4.6%	-	-
Total	586.5	600.0	583.0	-3.5	-0.6%	-17.0	-2.8%

Unit : Billion Yen	Operating Income						
	25/3 Results	26/3 Forecasts	26/3 Revised forecasts	Y on Y		vs Forecasts	
				Change	%	Change	%
Medical / Healthcare	0.3	0.3	0.4	+0.1	+53.3%	+0.1	+33.3%
Smart	-0.8	1.4	1.3	+2.1	-	-0.1	-7.1%
Safety	3.9	6.4	6.5	+2.6	+65.4%	+0.1	+1.6%
Materials	29.6	23.0	20.0	-9.6	-32.5%	-3.0	-13.0%
Engineering Plastics	27.0	22.1	17.5	-9.5	-35.2%	-4.6	-20.8%
Others	1.0	0.8	0.8	-0.2	-17.1%	-	-
Total	61.0	54.0	46.5	-14.5	-23.8%	-7.5	-13.9%

EBITDA	
25/3 Results	26/3 Revised forecasts
1.3	1.4
2.0	3.8
11.1	14.6
49.6	38.1
36.8	30.3
1.6	1.3
102.4	89.5

Segment Information – Forecasts

■ Medical / Healthcare

Unit : Billion Yen	26/3 Forecasts	26/3 Revised forecasts	vs Forecasts	
			Change	%
Net Sales	15.5	16.0	+0.5	+3.2%
Operating Income	0.3	0.4	+0.1	+33.3%

【 VS Initial Forecast】 Net Sales & OP Up

Life Sciences: Net Sales Up (+1.9%)

- Although synthetic services in India are not growing as planned, chiral column-related sales are expected to exceed the initial plan due to higher-than-planned sales of stationary phases for pharmaceutical manufacturing in Europe.
- Approval and Sales of Daicel Injector P1 SC:
Daicel Medical Ltd. obtained PMDA approval for its Gas-powered Needle-free Injector, "Daicel Injector P1 SC" in Japan on October 29, 2025. We plan to launch the product from the third quarter of the fiscal year ending March 2026.



Healthcare: Net Sales Up (+6.1%)

- The trend in cosmetics and health food markets in Japan and overseas are steady. Sales for supplements are stronger than initially expected. In particular, further growth in sales of equol is expected to exceed the initial plan.

Segment Information – Forecasts

■ Smart

Unit : Billion Yen	26/3 Forecasts	26/3 Revised forecasts	vs Forecasts	
			Change	%
Net Sales	40.5	39.0	-1.5	-3.7%
Operating Income	1.4	1.3	-0.1	-7.1%

【 VS Initial Forecast】 Net Sales & OP Down

Functional Products: Net Sales Up (+1.0%)

- Caprolactone derivatives are expected to fall short of initial plans due to intensifying price competition in China. We will make efforts to expand market share in Europe and the U.S. and expand new projects to overcome price competition in China.
- Regarding Cycloaliphatic epoxies, demand for electronic materials markets, such as electronic substrates, is expected to increase as planned. Initiatives to expand market share in Europe and the U.S progressing favorably, contributing to increased sales..

Advanced Technology: Net Sales Down (-8.4%)

- Solvent sales for electronic materials remained in line with initial plans due to sluggish demand overseas for automotive coatings in Europe, although the semiconductor market is growing primarily driven by AI applications.
- Photoresist materials are performing as expected, with demand from domestic semiconductor resist manufacturers growing, and are projected to meet initial plans (production timing shifts experienced by a customer in the first half are planned to be resolved in the second half).
- Functional films will fall short of initial plans due to delays in new product development, but we are implementing recovery measures such as restructuring sales strategies and launching new products.

Segment Information – Forecasts

■ Safety

Unit : Billion Yen	26/3 Forecasts	26/3 Revised forecasts	vs Forecasts	
			Change	%
Net Sales	101.0	103.5	+2.5	+2.5%
Operating Income	6.4	6.5	+0.1	+1.6%

【 VS Initial Forecast】 Net Sales & OP Up

Mobility: Net Sales Up (+4.0%)

- Although sales volume of automotive airbag inflators is expected to decrease slightly due to the impact of U.S. tariffs and lower-than-planned growth in Japanese automobile production, revenue is projected to increase due to favorable exchange rates. Efforts will focus on expanding sales to manufacturers other than Japanese and Chinese companies to increase market share.

Industry: Net Sales Down (-13.2%)

- While expanding into new applications, Pyro-Fuse is expected to fall short of initial plans due to OEMs revising their EV strategies and delays in mass production for certain vehicle models.

Segment Information – Forecasts

■ Materials

Unit : Billion Yen	26/3 Forecasts	26/3 Revised forecasts	vs Forecasts	
			Change	%
Net Sales	181.5	172.0	-9.5	-5.2%
Operating Income	23.0	20.0	-3.0	-13.0%

【 VS Initial Forecast】 Net Sales & OP Down

Acetyl : Net Sales Down (-5.6%)

- Sales of acetate tow to major tobacco manufacturers are on track, but sales to local manufacturers are struggling to expand due to inventory adjustments, resulting in net sales expected to fall below initial plans.
- Operating Income is expected to be lower than the initial plan, partly due to unplanned CO plant troubles.

Chemical : Net Sales Down (-4.1%)

- For cellulose acetate, while liquid crystal display applications are expected to meet initial plans due to pre-tariff demand in the U.S. and expanded overseas sales, fiber applications continue to be sluggish demand in the Chinese market. Overall, performance is projected to fall short of initial plans.
- 1,3-BG is expected to exceed initial forecasts, primarily driven by expanded sales to China and Europe.

Segment Information – Forecasts

■ Engineering Plastics

Unit : Billion Yen	26/3 Forecasts	26/3 Revised Forecasts	vs Forecasts	
			Change	%
Net Sales	256.0	247.0	-9.0	-3.5%
Operating Income	22.1	17.5	-4.6	-20.8%

【 VS Initial Forecast】 Net Sales & OP Down

Polyplastics: Net Sales Down (-3.6%)

Automobile production volume is expected to remain in line with initial plans. While sales of LCP and other products continued to perform well, net sales and operating income is expected to decrease due to factors such as reduced sales volumes of POM and COC.

- POM sales volumes are expected to fall below initial projections due to decreased demand from various industries in China and price competition in general-purpose POM. However, we are strengthening price management and organizational structures to defend our market share and secure profitability.
- Sales volume of COC are expected to fall below initial plans due to delays in expansion plans for environmentally friendly packaging materials.

Segment Information – Forecasts (YoY)

Unit : Billion Yen

		25/3 Results	26/3 Revised Forecasts*	Change	Y on Y
Medical / Healthcare	Net Sales	14.4	16.0	+1.6	Net Sales & OP Up - Life Sciences business is expected to remain nearly unchanged from the previous fiscal year. - In the Healthcare business, cosmetic ingredients and health food ingredients are expected to perform well, with particularly strong sales of equol in the health food ingredients segment.
	Operating Income	0.3	0.4	+0.1	
Smart	Net Sales	37.3	39.0	+1.7	Net Sales & OP Up - Sales of caprolactone derivatives are expected to remain at the previous fiscal year's level, while cycloaliphatic epoxies are projected to increase sales through sales expansion. - For solvents and photoresist materials for electronic materials, increased revenue is planned through expanded sales, supported by the steady performance of the domestic semiconductor market. - Functional films are expected to see increased revenue through recovery driven by newly developed products.
	Operating Income	-0.8	1.3	+2.1	
Safety	Net Sales	97.6	103.5	+5.9	Net Sales & OP Up While global automobile production volume is expected to remain flat, our sales volume of automotive airbag inflators is projected to increase, primarily in China and India, leading to higher net sales.
	Operating Income	3.9	6.5	+2.6	

*Figures announced on November 6, 2025.

Segment Information – Forecasts (YoY)

Unit : Billion Yen

		25/3 Results	26/3 Revised Forecasts*	Change	Y on Y
Materials	Net Sales	183.4	172.0	-11.4	Net Sales & OP Down - Sales to major tobacco manufacturers are expected to remain at the previous period's level, but sales to local manufacturers are projected to decline due to challenges in expanding sales amid inventory adjustments and the impact of foreign exchange rates. - Operating income is projected to decrease due to the impact of carryover inventory and foreign exchange rates, despite improvements from CO plant troubles.
	Operating Income	29.6	20.0	-9.6	
Engineering Plastics	Net Sales	248.0	247.0	-1.0	Net Sales & OP Down While LCP sales for servers remain strong, POM sales are projected to decline due to sluggish sales in the Chinese market, including a drop in exports from China to the U.S., compounded by foreign exchange impacts. Operating Income is also expected to decrease due to foreign exchange effects, increased maintenance costs and depreciation, as well as higher personnel and ICT-related expenses.
	Operating Income	27.0	17.5	-9.5	

Shareholders Return

Maintain stable shareholders return in accordance with the following policies; "total return ratio of 40% or more" and "dividend on equity (DOE) ratio of 4% or more"


FY ended March 2025

- **Year-end dividends : 30 yen per share**
(Annual dividends : 60 yen per share: increase by 10 yen from previous fiscal year)
- Purchase of own stocks of 10.98 million shares for 15 billion yen (Period of purchase: from Nov. 2024 to Feb. 2025)


FY ending March 2026

- Interim dividends : 30 yen per share
- Year-end dividends forecasts : 30 yen per share
(Annual dividends forecasts : 60 yen per share: same amount of dividends compared to the previous fiscal year)
- **Decided to purchase treasury stock of 15 billion yen for 11 million shares.(Period of purchase: From Nov. 2025 to Mar. 2026)**

Trends in Income Attributable to Owners of Parent and Dividends in Total Return (Unit: Billion Yen)




Trend in Shareholder Return Indices



Appendix

Cash Allocation and Cross-shareholdings

- **Cash generation capacity remains at the same level as in the Medium-Term Management Strategy**, and cash allocation will be flexibly reviewed to **allocate to growth investments and strengthen shareholder returns**.
- We have continued to reduce cross-shareholdings, and as of the end of March 2025, **the ratio of net assets including deemed holdings was less than 20%.**




Status of reduction in cross-shareholdings

	2025/3 Result	2026/3 Plan
Ratio of consolidated net assets (excluding deemed holdings of shares)	12.2%	7.8%
Ratio of consolidated net asse (including deemed holdings of shares)	17.0%	13.4%

Trend in Net Sales, Operating Income, and EPS


● Methanol(Asian spot price)(USD / ton)



■ Net Sales(billion yen)

□ Operating Income(billion yen)

◆ EPS (yen)



* The forecasts were announced on November 6, 2025.

Forecasts

Quarterly Results for Sales and Operating Income

Unit : Billion Yen	Net Sales					
	2025/3				2026/3	
	1Q	2Q	3Q	4Q	1Q	2Q
Medical / Healthcare	3.5	3.7	3.7	3.6	3.8	3.8
Smart	10.3	9.3	8.9	8.8	9.5	8.7
Safety	23.3	23.8	25.7	24.8	24.5	25.3
Materials	44.5	44.0	40.7	54.2	40.3	36.9
Engineering Plastics	62.7	61.8	62.3	61.2	59.9	62.0
Others	1.3	1.6	1.6	1.4	1.3	1.2
Total	145.6	144.1	142.9	154.0	139.3	137.8

Unit : Billion Yen	Operating Income					
	2025/3				2026/3	
	1Q	2Q	3Q	4Q	1Q	2Q
Medical / Healthcare	0.1	0.1	0.2	-0.1	0.2	0.0
Smart	0.5	-0.3	-0.8	-0.2	0.2	0.2
Safety	-0.0	1.4	1.7	0.9	1.6	1.1
Materials	9.1	5.3	4.8	10.5	4.4	0.6
Engineering Plastics	7.7	7.5	5.4	6.4	6.5	4.9
Others	0.1	0.2	0.4	0.3	0.1	0.3
Total	17.5	14.1	11.6	17.8	13.0	7.1

Financial Forecasts (FY ending March 2026)

Unit : Billion Yen		2026/3 Previous Forecasts			2026/3 Revised Forecasts*			Change (B)-(A)
		1st Half	2nd Half	Total(A)	1st Half	2nd Half	Total(B)	
	Medical / Healthcare	7.5	8.0	15.5	7.6	8.4	16.0	+0.5
	Smart	20.0	20.5	40.5	18.2	20.8	39.0	-1.5
	Safety	50.0	51.0	101.0	49.7	53.8	103.5	+2.5
	Materials	83.0	98.5	181.5	77.2	94.8	172.0	-9.5
	Engineering Plastics	127.0	129.0	256.0	121.9	125.1	247.0	-9.0
	Others	2.5	3.0	5.5	2.5	3.0	5.5	-
Net Sales		290.0	310.0	600.0	277.1	305.9	583.0	-17.0
	Medical / Healthcare	-0.2	0.5	0.3	0.2	0.2	0.4	+0.1
	Smart	0.7	0.7	1.4	0.4	0.9	1.3	-0.1
	Safety	2.9	3.5	6.4	2.7	3.8	6.5	+0.1
	Materials	7.8	15.2	23.0	5.0	15.0	20.0	-3.0
	Engineering Plastics	11.0	11.1	22.1	11.5	6.0	17.5	-4.6
	Others	0.3	0.5	0.8	0.4	0.4	0.8	-
Operating Income		22.5	31.5	54.0	20.1	26.4	46.5	-7.5
Ordinary Income		23.5	32.5	56.0	20.4	27.1	47.5	-8.5
Profit Attributable to Owners of Parent		25.0	29.0	54.0	18.8	31.2	50.0	-4.0
(ref.)Exchange rate USD/JPY		140	140	140	146	145	146	

* The forecasts were announced on November 6, 2025.

Capital Expenditures

Unit : Billion Yen	2021/3 Results	2022/3 Results	2023/3 Results *1	2023/3 Results *1,2	2024/3 Results *1	2024/3 Results *1,3	2025/3 Results *1	26/3 1H Results *1	26/3 Forecasts *1
Medical / Healthcare	8.7	1.0	2.7	2.2	1.9	1.9	0.9	0.8	1.5
Smart	2.0	2.9	4.2	4.2	2.6	3.0	2.3	0.8	4.0
Safety	8.8	7.7	9.0	9.0	9.4	9.4	11.0	5.8	12.0
Materials	11.6	18.8	8.6	9.1	17.4	16.9	11.5	15.0	24.0
Engineering Plastics	7.1	7.4	30.6	30.6	45.7	45.7	43.3	20.8	29.0
Others / Corporate	1.4	3.0	1.2	1.2	0.4	0.4	0.3	0.3	0.5
Total	39.6	40.8	56.3	56.3	77.5	77.5	69.5	43.4	71.0

*1 Reflects the revised method of allocating corporate expenses. Figures for "Others / Corporate" are only for "Other Businesses."

*2 Reflects segment changes effective April 1, 2023 in the Cosmetics Raw Material 1,3-BG and Novel Drug Delivery Devices R&D functions.

*3 Reflects segment changes effective April 1, 2024 in the TAC, Cycloaliphatic Epoxies and Caprolactone Derivatives.

Depreciation and Amortization

Unit : Billion Yen	2021/3 Results	2022/3 Results	2023/3 Results *1	2023/3 Results *1,2	2024/3 Results *1	2024/3 Results *1,3	2025/3 Results *1	26/3 1H Results *1	26/3 Forecasts *1
Medical / Healthcare	1.4	1.4	2.8	1.5	1.1	1.1	1.1	0.5	1.0
Smart	1.6	2.0	2.7	2.7	2.9	3.1	2.8	1.2	2.5
Safety	4.7	5.0	6.5	6.5	7.1	7.1	7.1	3.6	8.0
Materials	9.0	9.0	9.7	11.0	13.1	12.9	19.9	8.6	18.0
Engineering Plastics	6.9	7.0	8.6	8.6	8.2	8.2	9.5	6.0	12.5
Others / Corporate	2.2	2.5	0.6	0.6	0.6	0.6	0.6	0.2	0.5
Total	25.8	26.9	30.8	30.8	33.0	33.0	41.0	20.1	42.5

*1 Reflects the revised method of allocating corporate expenses. Figures for "Others / Corporate" are only for "Other Businesses."

*2 Reflects segment changes effective April 1, 2023 in the Cosmetics Raw Material 1,3-BG and Novel Drug Delivery Devices R&D functions.

*3 Reflects segment changes effective April 1, 2024 in the TAC, Cycloaliphatic Epoxies and Caprolactone Derivatives.

Unit : Billion Yen

	2021/3 Results	2022/3 Results	2023/3 Results *1	2023/3 Results *1,2	2024/3 Results *1	2024/3 Results *1,3	2025/3 Results *1	26/3 1H Results *1	26/3 Forecasts *1
Medical / Healthcare	2.1	1.9	2.2	2.8	2.4	2.4	2.7	1.4	3.0
Smart	2.7	3.6	4.2	4.2	4.0	4.8	5.0	2.1	4.2
Safety	5.1	5.6	6.3	5.7	6.0	6.0	7.2	3.9	8.0
Materials	1.6	1.5	2.8	2.8	3.8	3.1	3.5	1.9	3.5
Engineering Plastics	3.5	3.7	6.1	6.1	6.8	6.8	7.3	3.8	8.0
Others / Corporate	4.6	4.5	0.3	0.3	0.3	0.3	0.3	0.1	0.3
Total	19.5	20.7	21.9	21.9	23.4	23.4	25.9	13.1	27.0

*1 Reflects the revised method of allocating corporate expenses. Figures for "Others / Corporate" are only for "Other Businesses."

*2 Reflects segment changes effective April 1, 2023 in the Cosmetics Raw Material 1,3-BG and Novel Drug Delivery Devices R&D functions.

*3 Reflects segment changes effective April 1, 2024 in the TAC, Cycloaliphatic Epoxies and Caprolactone Derivatives.

Assumptions

		2024/3 (Results)		2025/3 (Forecasts)	2026/3	
		1st Half	2nd Half	Full year	1st Half (Result)	2nd Half (Forecasts)
Exchange rate (USD/JPY)		153	152	140	146	145
Raw Materials	Methanol Asian spot price (USD/ton)	332	334	330	307	330
	Crude Oil Dubai (USD/bbl.)	82	75	75	69	70
	Domestic Naphtha (JPY/kl)	77,950	74,000	67,000	65,150*	63,000

*As of October, 2025

Main Products List of Each Segment

Segment	Main Business	Main Products
Medical / Healthcare	Life Sciences	Chromatographic columns/stationary phases (chiral columns and achiral columns), Chiral reagents, Separation services/purification services, Analytical services, Reagents for genetic analysis research, Novel drug delivery devices
	Healthcare	Cosmetic ingredients (Polyglycerols, Spherical cellulose acetate particles (BELLOCEA®), etc.), Functional food ingredients (Equol, Konjac ceramide, Urolithin, and Lactobionic acid, etc.)
Smart	Functional Products	Cycloaliphatic epoxies, Caprolactone derivatives, Optical lenses
	Advanced Technology	Polymers for photoresists, Solvents for electronic materials, High-performance films
Safety	Mobility	Automobile airbag inflators
	Industry	Pyro-Fuse, Gas generators for seat belt pretensioners (PGG)
Materials	Acetyl	Acetic acid, Acetic anhydride, Acetate tow
	Chemical	Cellulose acetate for optical films (TAC)*, Cellulose acetate, 1,3-Butylene glycol (1,3-BG), Organic solvents such as Ethyl acetate, Ketene derivatives, Ethylamine
Engineering Plastics	Polyplastics Co., Ltd.	Polyacetal (POM), Polybutylene terephthalate (PBT), Polyphenylene sulfide (PPS), Liquid crystal polymer (LCP), Cyclic olefin copolymer (COC)
	Daicel Miraizu Ltd.	Water-soluble polymers (CMC), Barrier films for packaging and AS resin

External Recognition of ESG Indices

Daicel Group is working to create a sustainable society together with our customers and partners in order to realize a recycling-oriented society.

Daicel has been selected as a constituent stock of **all six ESG indices for domestic stocks adopted by the Government Pension Investment Fund (GPIF)**, one of the world's largest pension funds. (As of October, 2025)
Furthermore, in the 2025 MSCI ESG Ratings, our group **received an "AA" rating**.

- ◆ MSCI Nihonkabu ESG Select Leaders Index
- ◆ MSCI Japan Empowering Women Index (WIN)
- ◆ S&P/JPX Carbon Efficient Index
- ◆ FTSE Blossom Japan Index
- ◆ FTSE Blossom Japan Sector Relative Index
- ◆ Morningstar Japan ex-REIT Gender Diversity Tilt Index

2025 CONSTITUENT MSCI NIHONKABU
ESG SELECT LEADERS INDEX

MSCI
ESG RATINGS



CCC B BB BBB A AA AAA

2025 CONSTITUENT MSCI JAPAN
EMPOWERING WOMEN INDEX (WIN)



FTSE Blossom
Japan Index



FTSE Blossom
Japan Sector
Relative Index



Awarded the "Gold" medal in the
**2025 Sustainability Rating by
EcoVadis** (Head Office: France).



We have been certified as a "2025 KENKO
Investment for Health Excellent
Corporation (Large Corporation Category
"White 500")" (Daicel: 6th consecutive
year)



In addition, Daicel was selected for JPX-Nikkei Index Human Capital 100 in August 2025, and has been continuously selected for the FTSE4Good Index Series and SOMPO Sustainability Index, and has also been newly included in the iSTOXX® MUTB Japan Platinum Carrier 150 Index from May 2024.

※For details on each index, please refer to our web site.

[Participation in Initiatives and External Recognition | Sustainability | Daicel Corporation](#)

Notes Regarding Forward-Looking Statements

- **The purpose of this document is to provide information and not to persuade any individual to take any action in response to the information contained in this document. Daicel has made the greatest possible effort to prepare this document with accurate information. The information in this document, however, may include risks or inaccuracy, and we do not guarantee the accuracy or reliability of this information.**
- **The reader is advised that the use of the information in this document is at your own risk. Any investment according to the prospects, target values, etc. appearing in this document might result in a loss. Daicel accepts no responsibility for such an eventuality.**

- **All rights reserved by Daicel Corporation.**
- **This document shall not be copied or distributed to a third party without the permission of Daicel Corporation.**

This document is an English translation of a statement written originally in Japanese for reference. The Japanese original should be considered as the primary version.